Maurizio Ricci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4011226/publications.pdf

Version: 2024-02-01

103 papers

4,033 citations

94381 37 h-index 59 g-index

106 all docs

 $\begin{array}{c} 106 \\ \\ \text{docs citations} \end{array}$

106 times ranked 5371 citing authors

#	Article	IF	CITATIONS
1	Bioadhesive patches based on carboxymethyl cellulose/polyvinylpyrrolidone/bentonite composites and SoluplusÂ $^{\circ}$ for skin administration of poorly soluble molecules. Applied Clay Science, 2022, 216, 106377.	2.6	7
2	Wound Dressing: Combination of Acacia Gum/PVP/Cyclic Dextrin in Bioadhesive Patches Loaded with Grape Seed Extract. Pharmaceutics, 2022, 14, 485.	2.0	12
3	Pharmaceutically Active Microbial AhR Agonists as Innovative Biodrugs in Inflammation. Pharmaceuticals, 2022, 15, 336.	1.7	5
4	Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite., 2022, 10, e003725.		39
5	MgAl and ZnAl-Hydrotalcites as Materials for Cosmetic and Pharmaceutical Formulations: Study of Their Cytotoxicity on Different Cell Lines. Pharmaceuticals, 2022, 15, 784.	1.7	5
6	Taxifolin stability: In silico prediction and inÂvitro degradation with HPLC-UV/UPLC–ESI-MS monitoring. Journal of Pharmaceutical Analysis, 2021, 11, 232-240.	2.4	12
7	Development and Characterization of Xanthan Gum and Alginate Based Bioadhesive Film for Pycnogenol Topical Use in Wound Treatment. Pharmaceutics, 2021, 13, 324.	2.0	25
8	Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics. Pharmaceutics, 2021, 13, 494.	2.0	3
9	Indole-3-Carboxaldehyde Restores Gut Mucosal Integrity and Protects from Liver Fibrosis in Murine Sclerosing Cholangitis. Cells, 2021, 10, 1622.	1.8	23
10	Development of sodium carboxymethyl cellulose based polymeric microparticles for in situ hydrogel wound dressing formation. International Journal of Pharmaceutics, 2021, 602, 120606.	2.6	18
11	Enteric formulated indole-3-carboxaldehyde targets the aryl hydrocarbon receptor for protection in a murine model of metabolic syndrome. International Journal of Pharmaceutics, 2021, 602, 120610.	2.6	22
12	Targeted Drug Delivery Technologies Potentiate the Overall Therapeutic Efficacy of an Indole Derivative in a Mouse Cystic Fibrosis Setting. Cells, 2021, 10, 1601.	1.8	15
13	Emulgel Loaded with Flaxseed Extracts as New Therapeutic Approach in Wound Treatment. Pharmaceutics, 2021, 13, 1107.	2.0	12
14	Development and in vitro-in vivo performances of an inhalable indole-3-carboxaldehyde dry powder to target pulmonary inflammation and infection. International Journal of Pharmaceutics, 2021, 607, 121004.	2.6	9
15	Hazelnut Shells as Source of Active Ingredients: Extracts Preparation and Characterization. Molecules, 2021, 26, 6607.	1.7	13
16	Exploring Taxifolin Polymorphs: Insights on Hydrate and Anhydrous Forms. Pharmaceutics, 2021, 13, .	2.0	0
17	Exploring Taxifolin Polymorphs: Insights on Hydrate and Anhydrous Forms. Pharmaceutics, 2021, 13, 1328.	2.0	6
18	Development and characterization of mucoadhesive-thermoresponsive gels for the treatment of oral mucosa diseases. European Journal of Pharmaceutical Sciences, 2020, 142, 105125.	1.9	37

#	Article	IF	CITATIONS
19	Polymeric Bioadhesive Patch Based on Ketoprofen-Hydrotalcite Hybrid for Local Treatments. Pharmaceutics, 2020, 12, 733.	2.0	9
20	Preparation and characterization of polymeric microparticles loaded with Moringa oleifera leaf extract for exuding wound treatment. International Journal of Pharmaceutics, 2020, 587, 119700.	2.6	22
21	Improved Achiral and Chiral HPLC-UV Analysis of Ruxolitinib in Two Different Drug Formulations. Separations, 2020, 7, 47.	1.1	7
22	Biocompatible alginate silica supported silver nanoparticles composite films for wound dressing with antibiofilm activity. Materials Science and Engineering C, 2020, 112, 110863.	3.8	60
23	Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline?. Pharmaceutics, 2020, 12, 624.	2.0	20
24	Bioadhesive Polymeric Films Based on Red Onion Skins Extract for Wound Treatment: An Innovative and Eco-Friendly Formulation. Molecules, 2020, 25, 318.	1.7	30
25	Flow nanoprecipitation of size-controlled <scp>d</scp> -leucine nanoparticles for spray-drying formulations. Reaction Chemistry and Engineering, 2019, 4, 1861-1868.	1.9	1
26	Development and Characterization of New Topical Hydrogels Based on Alpha Lipoic Acid—Hydrotalcite Hybrids. Cosmetics, 2019, 6, 35.	1.5	13
27	D-leucine microparticles as an excipient to improve the aerosolization performances of dry powders for inhalation. European Journal of Pharmaceutical Sciences, 2019, 130, 54-64.	1.9	14
28	A Novel Stabilizing Approach to Improve the Manufacturing of Biodegradable Microparticles Entrapping Plasticizing Active Molecules: the Case of 4-Methoxychalcone. Journal of Pharmaceutical Innovation, 2019, 14, 159-175.	1.1	1
29	Meeting the unmet: from traditional to cutting-edge techniques for poly lactide and poly lactide-co-glycolide microparticle manufacturing. Journal of Pharmaceutical Investigation, 2019, 49, 381-404.	2.7	44
30	Bioadhesive polymeric films based on usnic acid for burn wound treatment: Antibacterial and cytotoxicity studies. Colloids and Surfaces B: Biointerfaces, 2019, 178, 488-499.	2.5	37
31	Exploring the Nano Spray-Drying Technology as an Innovative Manufacturing Method for Solid Lipid Nanoparticle Dry Powders. AAPS PharmSciTech, 2019, 20, 19.	1.5	9
32	Folic acid-layered double hydroxides hybrids in skin formulations: Technological, photochemical and in vitro cytotoxicity on human keratinocytes and fibroblasts. Applied Clay Science, 2019, 168, 382-395.	2.6	35
33	Biodegradable composite porous poly(<scp>dl</scp> -lactide- <i>co</i> -glycolide) scaffold supports mesenchymal stem cell differentiation and calcium phosphate deposition. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 219-229.	1.9	17
34	Artificial apolipoprotein corona enables nanoparticle brain targeting. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 429-438.	1.7	63
35	Towards Targeting the Aryl Hydrocarbon Receptor in Cystic Fibrosis. Mediators of Inflammation, 2018, 2018, 1-7.	1.4	24
36	Development of Novel Indole-3-Aldehyde–Loaded Gastro-Resistant Spray-Dried Microparticles for Postbiotic Small Intestine Local Delivery. Journal of Pharmaceutical Sciences, 2018, 107, 2341-2353.	1.6	28

#	Article	IF	Citations
37	Reshaping antibiotics through hydrophobic drug-bile acid ionic complexation enhances activity against Staphylococcus aureus biofilms. International Journal of Pharmaceutics, 2017, 528, 144-162.	2.6	10
38	Montmorillonite–chitosan–chlorhexidine composite films with antibiofilm activity and improved cytotoxicity for wound dressing. Journal of Colloid and Interface Science, 2017, 491, 265-272.	5.0	70
39	The long and winding road to inhaled TB therapy: not only the bug's fault. Drug Development and Industrial Pharmacy, 2017, 43, 347-363.	0.9	15
40	The strategic relevance of manufacturing technology: An overall quality concept to promote innovation preventing drug shortage. International Journal of Pharmaceutics, 2017, 516, 144-157.	2.6	14
41	Alginate beads as a carrier for omeprazole/SBA-15 inclusion compound: A step towards the development of personalized paediatric dosage forms. Carbohydrate Polymers, 2015, 133, 464-472.	5.1	23
42	Dynamic behavior of a spring-powered micronozzle needle-free injector. International Journal of Pharmaceutics, 2015, 491, 91-98.	2.6	34
43	Chlorhexidine-loaded functionalized mesoporous MCM-41 poly(methylmethacrylate) based composites with Candida antibiofilm activity. RSC Advances, 2015, 5, 84827-84835.	1.7	6
44	Drug delivery system innovation and Health Technology Assessment: Upgrading from Clinical to Technological Assessment. International Journal of Pharmaceutics, 2015, 495, 1005-1018.	2.6	14
45	Powder, capsule and device: An imperative ménage à trois for respirable dry powders. International Journal of Pharmaceutics, 2015, 494, 40-48.	2.6	18
46	\hat{l}^2 -cyclodextrin hinders PLGA plasticization during microparticle manufacturing. Journal of Drug Delivery Science and Technology, 2015, 30, 375-383.	1.4	10
47	The Influence of Feedstock and Process Variables on the Encapsulation of Drug Suspensions by Sprayâ€Drying in Fast Drying Regime: The Case of Novel Antitubercular Drug–Palladium Complex Containing Polymeric Microparticles. Journal of Pharmaceutical Sciences, 2014, 103, 1255-1268.	1.6	18
48	Chitosan films containing mesoporous SBA-15 supported silver nanoparticles for wound dressing. Journal of Materials Chemistry B, 2014, 2, 6054.	2.9	75
49	Capreomycin inhalable powders prepared with an innovative spray-drying technique. International Journal of Pharmaceutics, 2014, 469, 132-139.	2.6	31
50	Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacin–palladium complex. International Journal of Pharmaceutics, 2013, 440, 273-282.	2.6	58
51	Capreomycin supergenerics for pulmonary tuberculosis treatment: Preparation, in vitro, and in vivo characterization. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 388-395.	2.0	43
52	Conformal polymer coatings for pancreatic islets transplantation. International Journal of Pharmaceutics, 2013, 440, 141-147.	2.6	16
53	Mesoporous Silicate MCM-41 as a Particulate Carrier for Octyl Methoxycinnamate: Sunscreen Release and Photostability. Journal of Pharmaceutical Sciences, 2013, 102, 1468-1475.	1.6	39
54	Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity. International Journal of Pharmaceutics, 2013, 454, 316-323.	2.6	45

#	Article	IF	CITATIONS
55	Lipid nanoparticles for brain targeting II. Technological characterization. Colloids and Surfaces B: Biointerfaces, 2013, 110, 130-137.	2.5	32
56	Oxybenzone Entrapped in Mesoporous Silicate MCM-41. Journal of Pharmaceutical Innovation, 2013, 8, 212-217.	1.1	13
57	Synthesis, characterization and <i>in vitro</i> extracellular and intracellular activity against <i>Mycobacterium tuberculosis</i> infection of new second-line antitubercular drug-palladium complexes. Journal of Pharmacy and Pharmacology, 2013, 66, 106-121.	1,2	19
58	Response to Comment on Blasi et al. (2011) "Lipid nanoparticles for brain targeting I. Formulation optimization― International Journal of Pharmaceutics, 2012, 439, 171-174.	2.6	0
59	Montmorillonite as an agent for drug photostability. Journal of Materials Chemistry, 2012, 22, 22743.	6.7	25
60	Use of SBA-15 for furosemide oral delivery enhancement. European Journal of Pharmaceutical Sciences, 2012, 46, 43-48.	1.9	60
61	MCM-41 for furosemide dissolution improvement. Microporous and Mesoporous Materials, 2012, 147, 343-349.	2.2	66
62	Lipid nanoparticles for brain targeting I. Formulation optimization. International Journal of Pharmaceutics, 2011, 419, 287-295.	2.6	48
63	The real value of novel particulate carriers for sunscreen formulation. Expert Review of Dermatology, 2011, 6, 509-517.	0.3	16
64	Bioactive Long-Term Release from Biodegradable Microspheres Preserves Implanted ALG-PLO-ALG Microcapsules from In Vivo Response to Purified Alginate. Pharmaceutical Research, 2010, 27, 285-295.	1.7	13
65	Simple and scalable method for peptide inhalable powder production. European Journal of Pharmaceutical Sciences, 2010, 39, 53-58.	1.9	25
66	Development of a scalable procedure for fine calcium alginate particle preparation. Chemical Engineering Journal, 2010, 160, 363-369.	6.6	54
67	Lipid Nanoparticles for Drug Delivery to the Brain: <i>In Vivo Veritas</i> . Journal of Biomedical Nanotechnology, 2009, 5, 344-350.	0.5	16
68	Novel composite microparticles for protein stabilization and delivery. European Journal of Pharmaceutical Sciences, 2009, 36, 226-234.	1.9	54
69	Fighting tuberculosis: old drugs, new formulations. Expert Opinion on Drug Delivery, 2009, 6, 977-993.	2.4	38
70	Chitosan and a modified chitosan as agents to improve performances of mucoadhesive vaginal gels. Colloids and Surfaces B: Biointerfaces, 2008, 66, 141-145.	2.5	69
71	Physicochemical characterization and release mechanism of a novel prednisone biodegradable microsphere formulation. Journal of Pharmaceutical Sciences, 2008, 97, 303-317.	1.6	28
72	Role of mesoporous silicates on carbamazepine dissolution rate enhancement. Microporous and Mesoporous Materials, 2008, 113, 445-452.	2.2	64

#	Article	IF	Citations
73	Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. International Journal of Pharmaceutics, 2008, 357, 295-304.	2.6	229
74	Influence of Compression Force on The Behavior of Mucoadhesive Buccal Tablets. AAPS PharmSciTech, 2008, 9, 274-281.	1.5	20
75	Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery. International Journal of Pharmaceutics, 2007, 333, 103-111.	2.6	69
76	Solid lipid nanoparticles for targeted brain drug deliveryâ~†. Advanced Drug Delivery Reviews, 2007, 59, 454-477.	6.6	432
77	Ketoprofen poly(lactide-co-glycolide) physical interaction. AAPS PharmSciTech, 2007, 8, E78-E85.	1.5	76
78	Anionic clays for sunscreen agent safe use: Photoprotection, photostability and prevention of their skin penetration. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 62, 185-193.	2.0	96
79	Development of liposomal capreomycin sulfate formulations: Effects of formulation variables on peptide encapsulation. International Journal of Pharmaceutics, 2006, 311, 172-181.	2.6	52
80	Preparation and in vitro and in vivo characterization of composite microcapsules for cell encapsulation. International Journal of Pharmaceutics, 2006, 324, 27-36.	2.6	31
81	Analytical characterization of a ferulic acid/ \hat{l}^3 -cyclodextrin inclusion complex. Journal of Pharmaceutical and Biomedical Analysis, 2006, 40, 875-881.	1.4	64
82	Evaluation and Optimization of the Conditions for an Improved Ferulic Acid Intercalation into a Synthetic Lamellar Anionic Clay. Pharmaceutical Research, 2006, 23, 604-613.	1.7	7
83	Delivering Drugs to the Central Nervous System: A Medicinal Chemistry or a Pharmaceutical Technology Issue?. Current Medicinal Chemistry, 2006, 13, 1757-1775.	1.2	48
84	Long-term delivery of superoxide dismutase and catalase entrapped in poly(lactide-co-glycolide) microspheres: In vitro effects on isolated neonatal porcine pancreatic cell clusters. Journal of Controlled Release, 2005, 107, 65-77.	4.8	56
85	Ketoprofen controlled release from composite microcapsules for cell encapsulation: Effect on post-transplant acute inflammation. Journal of Controlled Release, 2005, 107, 395-407.	4.8	83
86	Evaluation of Indomethacin Percutaneous Absorption from Nanostructured Lipid Carriers (NLC): In Vitro and In Vivo Studies. Journal of Pharmaceutical Sciences, 2005, 94, 1149-1159.	1.6	102
87	Novel mucoadhesive buccal formulation containing metronidazole for the treatment of periodontal disease. Journal of Controlled Release, 2004, 95, 521-533.	4.8	153
88	Development of mucoadhesive patches for buccal administration of ibuprofen. Journal of Controlled Release, 2004, 99, 73-82.	4.8	208
89	Biodegradable microspheres as carriers for native superoxide dismutase and catalase delivery. AAPS PharmSciTech, 2004, 5, 1-9.	1.5	66
90	Leucinostatin-A loaded nanospheres: characterization and in vivo toxicity and efficacy evaluation. International Journal of Pharmaceutics, 2004, 275, 61-72.	2.6	25

#	Article	IF	CITATIONS
91	UV spectroscopy and reverse-phase HPLC as novel methods to determine Capreomycin of liposomal fomulations. Journal of Pharmaceutical and Biomedical Analysis, 2004, 36, 249-255.	1.4	22
92	Potential prodrugs of non-steroidal anti-inflammatory agents for targeted drug delivery to the CNS. European Journal of Medicinal Chemistry, 2004, 39, 715-727.	2.6	41
93	Unilamellar vesicles as potential capreomycin sulfate carriers: Preparation and physicochemical characterization. AAPS PharmSciTech, 2003, 4, 549-560.	1.5	22
94	New Oligoethylene Ester Derivatives of 5â€iodoâ€2â€2â€deoxyuridine as Dermal Prodrugs: Synthesis, Physicochemical Properties, and Skin Permeation Studies. Journal of Pharmaceutical Sciences, 2002, 91, 171-179.	1.6	11
95	Evaluation of in vitro percutaneous absorption of lorazepam and clonazepam from hydro-alcoholic gel formulations. International Journal of Pharmaceutics, 2001, 228, 79-87.	2.6	48
96	Improved function of rat islets upon co-microencapsulation with Sertoli's cells in alginate/poly-L-ornithine. AAPS PharmSciTech, 2001, 2, 48-54.	1.5	34
97	Antimicrobial Nonapeptide Leucinostatin A-Dependent Effects on the Physical Properties of Phospholipid Model Membranes. Journal of Colloid and Interface Science, 2000, 226, 222-230.	5.0	39
98	Liposome-based formulations for the antibiotic nonapeptide Leucinostatin A: Fourier transform infrared spectroscopy characterization and in vivo toxicologic study. AAPS PharmSciTech, 2000, 1, 9-19.	1.5	3
99	Liposome-based formulations for the antibiotic nonapeptide Leucinostatin A: Fourier transform infrared spectroscopy characterization and in vivo toxicologic study. AAPS PharmSciTech, 2000, 1, 9-19.	1.5	4
100	Antibody-targeted leucinostatin A. Journal of Controlled Release, 1994, 32, 37-44.	4.8	2
101	The nonapeptide leucinostatin A acts as a weak ionophore and as an immunosuppressant on T lymphocytes. Biochimica Et Biophysica Acta - Molecular Cell Research, 1994, 1221, 125-132.	1.9	31
102	Leucinostatin D. A novel peptide antibiotic from Paecilomyces marquandii Journal of Antibiotics, 1987, 40, 130-133.	1.0	42
103	Leucinostatins H and K, two novel peptide antibiotics with tertiay amine-oxide terminal group from Paecilomyces marquandii Isolation, structure and biological activity Journal of Antibiotics, 1987, 40, 714-716.	1.0	39